Potassium Phosphates in Sodium Chloride Injection is indicated as a source of phosphorus to correct hypophosphatemia in adults and pediatric patients who weigh 40 kg or greater when oral or enteral replacement is not possible, insufficient, or contraindicated.
Potassium Phosphates in Sodium Chloride Injection is for intravenous infusion into a central or peripheral vein. No dilution of this product is required. Use this potassium phosphates in sodium chloride injection product only in patients who require the entire 15 mmoL phosphorus dose (potassium 22 mEq) and not any fraction thereof. If a dose of potassium phosphate is required that does not equal 15 mmoL of Potassi...
Potassium Phosphates in 0.9% Sodium Chloride Injection is a clear, colorless solution filled in an intravenous infusion bag containing phosphorus 15 mmol/250 mL (0.06 mmol/mL) and potassium 22mEq/250mL (0.088 mEq/mL). It is supplied as: One 250 mL Single-dose Infusion Bag in a Pouch: NDC 70121-1722-1 24 Pouches in a Shipper (Unit of sale): NDC 70121-1722-9 Store at 2...
www.fda.gov/medwatch
www.amneal.comPotassium Phosphates in Sodium Chloride Injection is indicated as a source of phosphorus to correct hypophosphatemia in adults and pediatric patients who weigh 40 kg or greater when oral or enteral replacement is not possible, insufficient, or contraindicated.
TABLE 1: Recommended Initial or Single Doses of Potassium Phosphates to Correct Hypophosphatemia in Adults and Pediatric Patients Weighing 40 kg or Greater
Serum Phosphorus Concentrationa | Phosphorus Dosageb, c | Corresponding Potassium Content |
1.8 mg/dL to lower end of the reference rangea | 0.16 mmol/kg to 0.31 mmol/kg | Potassium 0.23 mEq/kg to 0.46 mEq/kg |
1 mg/dL to 1.7 mg/dL | 0.32 mmol/kg to 0.43 mmol/kg | Potassium 0.47 mEq/kg to 0.63 mEq/kg |
Less than 1 mg/dL | 0.44 mmol/kg to 0.64 mmol/kgc | Potassium 0.64 mEq/kg to 0.94 mEq/kg |
a Serum phosphorus reported using 2.5 mg/dL as the lower end of the reference range for healthy adults and pediatric patients 12 months of age and older. Serum phosphorus concentrations may vary depending on the assay used and the laboratory reference range. b Weight is in terms of actual body weight. Limited information is available regarding dosing of patients significantly above ideal body weight; consider using an adjusted body weight for these patients. c This single-dose preparation of Potassium Phosphates in Sodium Chloride Injection contains phosphorus 15 mmol and potassium 22 mEq. Additional dose(s) following the initial dose may be needed in some patients. | ||
Intravenous Infusion Rate
TABLE 2: Maximum Recommended Infusion Rate of Potassium Phosphates in Sodium Chloride Injection for Adults and Pediatric Patients Weighing 40 kg or Greater
Route of Administration | Maximum Infusion Rate |
Peripheral Venous Catheter | phosphorus 6.8 mmol/hour (potassium 10 mEq/hour) |
Central Venous Catheter | phosphorus 15 mmol/hour (potassium 22 mEq/hour) |
Continuous electrocardiographic (ECG) monitoring and infusion through a central venous catheter is recommended for infusion rates higher than potassium 10 mEq/hour.
Repeated Dosing
Additional dose(s) following the initial dose may be needed in some patients. Prior to administration of additional doses, assess the patient clinically, obtain serum phosphorus, calcium, and potassium concentrations and adjust the dose accordingly.
Potassium Phosphates in 0.9% Sodium Chloride Injection is a clear, colorless solution filled in a single-dose intravenous infusion bag and supplied as:
Potassium Phosphates in Sodium Chloride Injection is contraindicated in patients with:
Intravenous administration of potassium phosphates to correct hypophosphatemia in single-doses of phosphorus 50 mmol and greater and/or at rapid infusion rates (over 1 to 3 hours) has resulted in death, cardiac arrest, cardiac arrhythmia (including QT prolongation), hyperkalemia, hyperphosphatemia and seizures [see Overdosage (10)].
Potassium Phosphates in Sodium Chloride Injection is for intravenous infusion. No dilution of this product is required. The maximum initial or single-dose of potassium phosphates to correct hypophosphatemia is phosphorus 45 mmol (potassium 66 mEq). The recommended infusion rate for administration through a peripheral venous catheter is approximately phosphorus 6.8 mmol/hour (potassium 10 mEq/hour). Continuous electrocardiographic (ECG) monitoring is recommended for higher infusion rates [see Dosage and Administration (2.1, 2.2)].
Pulmonary vascular emboli and pulmonary distress related to precipitates in the pulmonary vasculature have been described in patients receiving admixed products containing calcium and phosphate. The cause of precipitate formation has not been determined in all cases; however, in some fatal cases, pulmonary emboli occurred as a result of calcium phosphate precipitates. Precipitation has occurred following passage through an in-line filter; in vivo precipitate formation may also have occurred. If signs of pulmonary distress occur, stop the infusion and initiate a medical evaluation. In addition to inspection of the solution [see Dosage and Administration (2.3)], the infusion set and catheter should also periodically be checked for precipitates.
Potassium Phosphates in Sodium Chloride Injection may increase the risk of hyperkalemia, including life-threatening cardiac events, especially when administered in excessive doses or by rapid intravenous infusion [see Warnings and Precautions (5.1)]. Patients with severe renal impairment and end stage renal disease are at increased risk of developing life-threatening hyperkalemia, when administered intravenous potassium [see Contraindications (4)]. Other patients at increased risk of hyperkalemia include those with severe adrenal insufficiency or treated concurrently with other drugs that cause or increase the risk of hyperkalemia [see Drug Interactions (7.1)]. Patients with cardiac disease may be more susceptible to the effects of hyperkalemia.
Consider the amount of potassium from all sources when determining the dose of Potassium Phosphates in Sodium Chloride Injection and do not exceed the maximum age-appropriate recommended daily amount of potassium. In patients with moderate renal impairment (eGFR ≥ 30 mL/min/1.73 m2 to < 60 mL/min/1.73 m2), start at the low end of the dose range and monitor serum potassium, phosphorus, calcium, and magnesium concentrations [see Dosage and Administration (2.2), Use in Specific Populations (8.6)].
When administering Potassium Phosphates in Sodium Chloride Injection to correct hypophosphatemia, check the serum potassium concentration prior to administration. If the potassium concentration is 4 mEq/dL or more, do not administer Potassium Phosphates in Sodium Chloride Injection and use an alternative source of phosphorus [see Dosage and Administration (2.1)].
The maximum initial or single-dose of potassium phosphates to correct hypophosphatemia is phosphorus 45 mmol (potassium 66 mEq). The recommended infusion rate of potassium through a peripheral venous catheter is 10 mEq/hour. Continuous electrocardiographic (ECG) monitoring is recommended for higher infusion rates of potassium [see Dosage and Administration (2.2)].
Hyperphosphatemia can occur with intravenous administration of potassium phosphates, especially in patients with renal impairment. Hyperphosphatemia can cause the formation of insoluble calcium phosphorus products with consequent hypocalcemia, neurological irritability with tetany, nephrocalcinosis with acute kidney injury and more rarely, cardiac irritability with arrhythmias.
Obtain serum calcium concentrations prior to administration and normalize the calcium before administering Potassium Phosphates in Sodium Chloride Injection. Potassium Phosphates in Sodium Chloride Injection is contraindicated in patients with hyperphosphatemia and/or hypercalcemia [see Contraindications (4)].
Monitor serum phosphorus and calcium concentrations during treatment with Potassium Phosphates in Sodium Chloride Injection [see Dosage and Administration (2.2)].
Intravenous infusion of phosphate has been reported to cause a decrease in serum magnesium (and calcium) concentrations when administered to patients with hypercalcemia and diabetic ketoacidosis. Monitor serum magnesium concentrations during treatment.
The infusion of potassium phosphates solutions into a peripheral vein may result in vein irritation, vein damage, and/or thrombosis. The primary complication of peripheral administration is venous thrombophlebitis, which manifests as pain, erythema, tenderness, or a palpable cord.
Monitor serum phosphorus, potassium, calcium, and magnesium concentrations during treatment [see Dosage and Administration (2.2)].
The following clinically significant adverse reactions are described elsewhere in the labeling:
The following adverse reactions in Table 3 have been reported in clinical studies or post-marketing reports in patients receiving intravenously administered potassium phosphates. Because some of these reactions were reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.
TABLE 3: Adverse Reactions Reported in Clinical Studies or Post-marketing Reports with Intravenous Potassium Phosphates
System Organ Class | Adverse Reactions |
Metabolism and Nutrition Disorders | pulmonary embolism due to pulmonary vascular precipitates [see Warnings and Precautions (5.2)], hyperkalemia [see Warnings and Precautions (5.3)], hyperphosphatemia [see Warnings and Precautions (5.4)], hypocalcemia [see Warnings and Precautions (5.4)], hypovolemia and osmotic diuresis |
Cardiac Disorders | hypotension, arrhythmia, heart block, cardiac arrest, bradycardia, chest pain, ECG changes [see Warnings and Precautions (5.1)] and edema |
Respiratory, Thoracic, and Mediastinal Disorders | dyspnea [see Warnings and Precautions (5.2)] |
Renal and Urinary Disorders | acute phosphate nephropathy (i.e., nephrocalcinosis with acute kidney injury), decreased urine output and transition to chronic kidney disease [see Warnings and Precautions (5.4)] |
Gastrointestinal Disorders | diarrhea, stomach pain |
Musculoskeletal and Connective Tissue Disorders | weakness |
Nervous System Disorders | confusion, lethargy, paralysis, paresthesia |
Administration of Potassium Phosphates in Sodium Chloride Injection to patients treated concurrently or recently with products that increase serum potassium (e.g., potassium-sparing diuretics, ACE inhibitors, angiotensin II receptor antagonists, digoxin, or the immunosuppressants tacrolimus and cyclosporine) increases the risk of severe and potentially fatal hyperkalemia, in particular in the presence of other risk factors for hyperkalemia [see Warnings and Precautions (5.3)]. Avoid use of Potassium Phosphates in Sodium Chloride Injection in patients receiving such products. If use cannot be avoided, closely monitor serum potassium concentrations [see Dosage and Administration (2.2)].
Risk Summary
Administration of the recommended dose of Potassium Phosphates in Sodium Chloride Injection is not expected to cause major birth defects, miscarriage, or adverse maternal or fetal outcomes. Consider potassium phosphate replacement if correction of hypophosphatemia via the enteral route is not possible (see Clinical Considerations). Animal reproduction studies have not been conducted with Potassium Phosphates in Sodium Chloride Injection.
The background risk of major birth defects and miscarriage for the indicated population is unknown. All pregnancies have a background risk of birth defect, loss, or other adverse outcomes. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2% to 4% and 15% to 20%, respectively.
Clinical Considerations
Disease-associated Maternal and/or Embryo-Fetal Risk
Phosphorus is an essential mineral element. Intravenous replacement with potassium phosphate should be considered if a pregnant woman requires intravenous replacement to correct hypophosphatemia when the enteral route is not possible, insufficient or contraindicated.
Risk Summary
Phosphorus and potassium are present in human milk. Administration of the recommended dose of Potassium Phosphates in Sodium Chloride Injection is not expected to cause harm to a breast-fed infant. There is no information on the effects of potassium phosphates on milk production. The development and health benefits of breastfeeding should be considered along with the mother’s clinical need for Potassium Phosphates in Sodium Chloride Injection and any potential adverse effects on the breastfed child from Potassium Phosphates in Sodium Chloride Injection or from underlying maternal condition.
Safety and effectiveness of Potassium Phosphates in Sodium Chloride Injection have been established in pediatric patients weighing 40 kg or more as a source of phosphorus to correct hypophosphatemia when oral or enteral replacement is not possible, insufficient, or contraindicated. However, this potassium phosphates in sodium chloride injection product is not approved for use in pediatric patients who weigh less than 40 kg because of the lack of an appropriate formulation.
In general, dose selection of Potassium Phosphates in Sodium Chloride Injection for an elderly patient should be cautious, starting at the low end of the dosing range because of the greater frequency of decreased hepatic, renal, or cardiac function and of concomitant disease or other drug therapy. It may be useful to monitor renal function during treatment [see Use in Specific Populations (8.6)].
Potassium and phosphorus are known to be substantially excreted by the kidney and the risk of adverse reactions to Potassium Phosphates in Sodium Chloride Injection may be greater in patients with impaired renal function [see Warnings and Precautions (5.3, 5.4)].
Potassium Phosphates in Sodium Chloride Injection is contraindicated due to the risk of hyperkalemia in patients with severe renal impairment (eGFR less than 30 mL/min/1.73 m2) or end stage renal disease [see Contraindications (4)].
In patients with moderate renal impairment (eGFR ≥ 30 mL/min/1.73 m2 to < 60 mL/min/1.73 m2), start at the low end of the dosage range and monitor serum potassium, phosphorus, calcium, and magnesium concentrations [see Dosage and Administration (2.2)].
Hyperphosphatemia
Administration of excessive doses of intravenous potassium phosphates as a single-dose ranging from approximately 50 to 270 mmol phosphorus and/or at rapid infusion rates (over 1 to 3 hours) has resulted in death, cardiac arrest, cardiac arrhythmia (including QT prolongation), hyperkalemia, hyperphosphatemia, seizures and tetany.
Hyperphosphatemia is particularly a risk in patients with renal failure. Hyperphosphatemia leads in turn to hypocalcemia, which may be severe and to ectopic calcification, particularly in patients with initial hypercalcemia. Tissue calcification may cause hypotension and organ damage and result in acute renal failure.
Hyperkalemia
Excessive administration of phosphates given as potassium salts may also cause hyperkalemia. Manifestations of hyperkalemia include:
Management
In the event of overdosage, discontinue infusions containing potassium phosphates immediately and institute general supportive measures, including ECG monitoring, laboratory monitoring and correction of serum electrolyte concentrations, especially potassium, phosphorus, calcium and magnesium.
Potassium Phosphates in 0.9% Sodium Chloride Injection, for intravenous use, is a phosphorus replacement product containing phosphorus 0.06 mmol/mL and potassium 0.088 mEq/mL. It is a sterile, non-pyrogenic, ready-to-use diluted solution containing a mixture of monobasic potassium phosphate, USP and dibasic potassium phosphate, USP in 0.9% sodium chloride. No dilution is required before administration. It is supplied in 250 mL single-dose intravenous infusion bag.
Monobasic Potassium Phosphate is chemically designated KH2PO4, molecular weight 136.09, white, odorless crystals or granules freely soluble in water.
Dibasic Potassium Phosphate is chemically designated K2HPO4, molecular weight 174.18, colorless or white granular salt freely soluble in water.
Each mL contains 4.48 mg of monobasic potassium phosphate, USP and 4.72 mg of dibasic potassium phosphate, USP.
Each mL contains phosphorus, 0.06 mmol (equivalent to 1.86 mg phosphorus); potassium, 0.088 mEq (equivalent to 3.40 mg of potassium); sodium chloride, USP, 9 mg and water for injection, USP (q.s.).
Note: 1 mmol of phosphorus is equal to 1 mmol phosphate.
This product contains no more than 25 mcg/L of aluminum.
The pH is 5.8 to 7.2 and the osmolarity is 0.455 mOsmol/mL (calc).
Phosphorus in the form of organic and inorganic phosphate has a variety of biochemical functions in all organs and tissues, including critical roles in nucleic acid structure, energy storage and transfer, cell signaling, cell membrane composition and structure, acid-base balance, mineral homeostasis, and bone mineralization.
The exposure-response relationship and time course of pharmacodynamic response for the safety and effectiveness of potassium phosphates have not been fully characterized.
Distribution
Approximately 85% of serum phosphates is free and ultra-filterable and 15% is protein-bound.
Elimination
Intravenously infused phosphates not taken up by the tissues are excreted almost entirely in the urine. Serum phosphorus is believed to be filterable by the renal glomeruli and the major portion of filtered phosphorus (greater than 80%) is actively reabsorbed by the tubules.
Potassium Phosphates in 0.9% Sodium Chloride Injection is a clear, colorless solution filled in an intravenous infusion bag containing phosphorus 15 mmol/250 mL (0.06 mmol/mL) and potassium 22mEq/250mL (0.088 mEq/mL). It is supplied as:
One 250 mL Single-dose Infusion Bag in a Pouch: NDC 70121-1722-1
24 Pouches in a Shipper (Unit of sale): NDC 70121-1722-9
Store at 20°C to 25°C (68°F to 77°F); excursions permitted between 15°C to 30°C (59°F to 86°F) [see USP Controlled Room Temperature]. Keep covered in a pouch until time of use.
Each ready-to-use infusion bag contains no preservatives. Once the ready-to-use infusion bag has been removed from the pouch, the ready-to-use infusion bag should be used within 24 hours, with any unused portion discarded.
Inform patients, caregivers, or home healthcare providers of the following risks of Potassium Phosphates in Sodium Chloride Injection:
For additional information go to www.amneal.com or call 1-877-835-5472.
Manufactured by:
Amneal Pharmaceuticals Pvt. Ltd.
Mehsana 382165, INDIA
Or
Amneal Pharmaceuticals Pvt. Ltd.
Ahmedabad 382110, INDIA
Distributed by:
Amneal Pharmaceuticals LLC
Bridgewater, NJ 08807
Rev. 09-2025-02
NDC 70121-1722-1 (Palli)
Potassium Phosphates in 0.9% Sodium Chloride Injection
Phosphorus 15 mmol/250 mL (0.06 mmol/ mL)
Potassium 22 mEq/250 mL (0.088 mEq/mL)
Intravenous Bag Label
Rx only
Amneal Pharmaceuticals LLC
NDC 70121-1722-1 (Palli)
Potassium Phosphates in 0.9% Sodium Chloride Injection
Phosphorus 15 mmol/250 mL (0.06 mmol/ mL)
Potassium 22 mEq/250 mL (0.088 mEq/mL)
Pouch Label
Rx only
Amneal Pharmaceuticals LLC
NDC 70121-1722-9 (Palli)
Potassium Phosphates in 0.9% Sodium Chloride Injection
Phosphorus 15 mmol/250 mL (0.06 mmol/ mL)
Potassium 22 mEq/250 mL (0.088 mEq/mL)
Carton Label
Rx only
Amneal Pharmaceuticals LLC
NDC 70121-1722-1 (Pipan)
Potassium Phosphates in 0.9% Sodium Chloride Injection
Phosphorus 15 mmol/250 mL (0.06 mmol/ mL)
Potassium 22 mEq/250 mL (0.088 mEq/mL)
Intravenous Bag Label
Rx only
Amneal Pharmaceuticals LLC
NDC 70121-1722-1 (Pipan)
Potassium Phosphates in 0.9% Sodium Chloride Injection
Phosphorus 15 mmol/250 mL (0.06 mmol/ mL)
Potassium 22 mEq/250 mL (0.088 mEq/mL)
Pouch Label
Rx only
Amneal Pharmaceuticals LLC
NDC 70121-1722-9 (Pipan)
Potassium Phosphates in 0.9% Sodium Chloride Injection
Phosphorus 15 mmol/250 mL (0.06 mmol/ mL)
Potassium 22 mEq/250 mL (0.088 mEq/mL)
Carton Label
Rx only
Amneal Pharmaceuticals LLC
| RxCUI | RxNorm string | TTY | SPL version |
|---|---|---|---|
| 2688947 | potassium phosphates (phosphorus 15 MMOL / potassium 22 MEQ) in 250 ML Injection | PSN | 5 |
| 2688947 | 250 ML dibasic potassium phosphate 4.72 MG/ML / monobasic potassium phosphate 4.48 MG/ML Injection | SCD | 5 |
| 2688947 | 250 ML dibasic K+ phosphate 4.72 MG/ML / monobasic K+ phosphate 4.48 MG/ML Injection | SY | 5 |
| 2688947 | 250 ML dibasic Pot phosphate 4.72 MG/ML / monobasic Pot phosphate 4.48 MG/ML Injection | SY | 5 |
| 2688947 | phosphorus 15 MMOL / potassium 22 MEQ per 250 ML Injection | SY | 5 |
| Package NDC | Product | Description | Form | Quantity | Strength | SPL version |
|---|---|---|---|---|---|---|
| 70121-1722-9 | POTASSIUM PHOSPHATES | 1 in 1 POUCH | INJECTION | 1 | 5 | |
| 70121-1722-9 | POTASSIUM PHOSPHATES | 24 in 1 CARTON | INJECTION | 24 | 5 |
| Package NDC | Billing unit | Product NDC | DailyMed indexing SPL | SPL version | Effective |
|---|---|---|---|---|---|
| 70121-1722-9 | ML - Milliliter | 70121-1722 | 138ad2a7-7b12-4ceb-98a2-72500d631171 | 1 | 2024-10-04 |
Every source-derived product name is available through these pages.
| Product NDC | Package NDC |
|---|---|
| 70121-1722 | 70121-1722-9 |
Every source-derived ingredient row is available through these pages.
| Name | UNII | Kind |
|---|---|---|
| POTASSIUM PHOSPHATE, MONOBASIC | 4J9FJ0HL51 | ACTIB |
| POTASSIUM PHOSPHATE, DIBASIC | CI71S98N1Z | ACTIB |
| SODIUM CHLORIDE | 451W47IQ8X | IACT |
| WATER | 059QF0KO0R | IACT |
All distinct exact application/product contexts derived from this label’s complete NDC list are paginated below.
| Application-product | Trade name | Ingredient | Strength | Dosage form / route | TE codes | RLD / RS | Approval date |
|---|---|---|---|---|---|---|---|
| N218343-001 | POTASSIUM PHOSPHATES IN 0.9% SODIUM CHLORIDE | POTASSIUM PHOSPHATE, DIBASIC; POTASSIUM PHOSPHATE, MONOBASIC | 1.18GM/250ML (4.72MG/ML);1.12GM/250ML (4.48MG/ML) | SOLUTION / INTRAVENOUS | RLD, RS | 2024-07-26 |
| Application-product | Patent | Expiration | Use code | Coverage / status | Submission date |
|---|---|---|---|---|---|
| N218343-001 | 11925661 | 2041-10-12 | U-4185 | Drug product | 2026-07-27 |
Observed FDA ZIP history: Each table is queried independently by exact application/product key from successfully parsed Orange Book snapshots. Capture times identify archived source observations; absence or a change between snapshots is not inferred. FDA publication files that were not recoverable as structured ZIP data are not represented as states.
| Captured | Edition | Application-product | Trade name | Strength | Dosage form / route | Product TE source text | RLD / RS | Approval date | Source SHA-256 |
|---|---|---|---|---|---|---|---|---|---|
| 2026-10-15 13:18:30 | 2026-09 | N218343-001 | POTASSIUM PHOSPHATES IN 0.9% SODIUM CHLORIDE | 1.18GM/250ML (4.72MG/ML);1.12GM/250ML (4.48MG/ML) | SOLUTION / INTRAVENOUS | RLD, RS | 2024-07-26 | c2088c7a36db… | |
| 2026-09-14 22:38:34 | 2026-08 | N218343-001 | POTASSIUM PHOSPHATES IN 0.9% SODIUM CHLORIDE | 1.18GM/250ML (4.72MG/ML);1.12GM/250ML (4.48MG/ML) | SOLUTION / INTRAVENOUS | RLD, RS | 2024-07-26 | 84e616aacf4f… | |
| 2026-08-18 06:07:40 | 2026-07 | N218343-001 | POTASSIUM PHOSPHATES IN 0.9% SODIUM CHLORIDE | 1.18GM/250ML (4.72MG/ML);1.12GM/250ML (4.48MG/ML) | SOLUTION / INTRAVENOUS | RLD, RS | 2024-07-26 | caaa826d4ba7… | |
| 2026-02-19 14:30 UTC | 2026-02 | N218343-001 | POTASSIUM PHOSPHATES IN 0.9% SODIUM CHLORIDE | 1.18GM/250ML (4.72MG/ML);1.12GM/250ML (4.48MG/ML) | SOLUTION / INTRAVENOUS | RLD, RS | 2024-07-26 | 011fe1cb6892… | |
| 2025-12-14 10:44 UTC · 2 captures of this ZIP | 2025-12 | N218343-001 | POTASSIUM PHOSPHATES IN 0.9% SODIUM CHLORIDE | 1.18GM/250ML (4.72MG/ML);1.12GM/250ML (4.48MG/ML) | SOLUTION / INTRAVENOUS | RLD, RS | 2024-07-26 | 31067a03dcf5… | |
| 2025-08-23 18:47 UTC | 2025-08 | N218343-001 | POTASSIUM PHOSPHATES IN 0.9% SODIUM CHLORIDE | 1.18GM/250ML (4.72MG/ML);1.12GM/250ML (4.48MG/ML) | SOLUTION / INTRAVENOUS | RLD, RS | 2024-07-26 | 6a471c1ec25d… | |
| 2025-03-22 03:13 UTC · 3 captures of this ZIP | 2025-03 | N218343-001 | POTASSIUM PHOSPHATES IN 0.9% SODIUM CHLORIDE | 1.18GM/250ML (4.72MG/ML);1.12GM/250ML (4.48MG/ML) | SOLUTION / INTRAVENOUS | RLD, RS | 2024-07-26 | fd3edfee7708… | |
| 2025-02-26 10:13 UTC · 3 captures of this ZIP | 2025-02 | N218343-001 | POTASSIUM PHOSPHATES IN 0.9% SODIUM CHLORIDE | 1.18GM/250ML (4.72MG/ML);1.12GM/250ML (4.48MG/ML) | SOLUTION / INTRAVENOUS | RLD, RS | 2024-07-26 | b8a1b40f171c… | |
| 2025-01-19 17:59 UTC · 7 captures of this ZIP | 2025-01 | N218343-001 | POTASSIUM PHOSPHATES IN 0.9% SODIUM CHLORIDE | 1.18GM/250ML (4.72MG/ML);1.12GM/250ML (4.48MG/ML) | SOLUTION / INTRAVENOUS | RLD, RS | 2024-07-26 | 03ed91905a0d… | |
| 2024-12-13 21:23 UTC · 2 captures of this ZIP | 2024-12 | N218343-001 | POTASSIUM PHOSPHATES IN 0.9% SODIUM CHLORIDE | 1.18GM/250ML (4.72MG/ML);1.12GM/250ML (4.48MG/ML) | SOLUTION / INTRAVENOUS | RLD, RS | 2024-07-26 | 2680178bc6a6… | |
| 2024-09-14 05:58 UTC · 2 captures of this ZIP | 2024-09 | N218343-001 | POTASSIUM PHOSPHATES IN 0.9% SODIUM CHLORIDE | 1.18GM/250ML (4.72MG/ML);1.12GM/250ML (4.48MG/ML) | SOLUTION / INTRAVENOUS | RLD, RS | 2024-07-26 | 5bbf6a4d5a75… | |
| 2024-11-08 22:44 UTC · 3 captures of this ZIP | 2024-11 | N218343-001 | POTASSIUM PHOSPHATES IN 0.9% SODIUM CHLORIDE | 1.18GM/250ML (4.72MG/ML);1.12GM/250ML (4.48MG/ML) | SOLUTION / INTRAVENOUS | RLD, RS | 2024-07-26 | d8e5a09893c0… | |
| 2024-10-29 15:01 UTC | 2024-10 | N218343-001 | POTASSIUM PHOSPHATES IN 0.9% SODIUM CHLORIDE | 1.18GM/250ML (4.72MG/ML);1.12GM/250ML (4.48MG/ML) | SOLUTION / INTRAVENOUS | RLD, RS | 2024-07-26 | d06236e962d9… | |
| 2024-08-13 05:28 UTC · 3 captures of this ZIP | 2024-08 | N218343-001 | POTASSIUM PHOSPHATES IN 0.9% SODIUM CHLORIDE | 1.18GM/250ML (4.72MG/ML);1.12GM/250ML (4.48MG/ML) | SOLUTION / INTRAVENOUS | RLD, RS | 2024-07-26 | 79d66fd596c7… | |
| 2026-07-26 02:55 UTC · 3 captures of this ZIP | 2026-06 | N218343-001 | POTASSIUM PHOSPHATES IN 0.9% SODIUM CHLORIDE | 1.18GM/250ML (4.72MG/ML);1.12GM/250ML (4.48MG/ML) | SOLUTION / INTRAVENOUS | RLD, RS | 2024-07-26 | a50c72e98297… |
| Captured | Edition | Application-product | Patent | Expiration | Use code | Coverage / status | Submission date | Source SHA-256 |
|---|---|---|---|---|---|---|---|---|
| 2026-10-15 13:18:30 | 2026-09 | N218343-001 | 11925661 | 2041-10-12 | U-4185 | Drug product | 2026-07-27 | c2088c7a36db… |
| 2026-09-14 22:38:34 | 2026-08 | N218343-001 | 11925661 | 2041-10-12 | U-4185 | Drug product | 2026-07-27 | 84e616aacf4f… |
| 2026-08-18 06:07:40 | 2026-07 | N218343-001 | 11925661 | 2041-10-12 | U-4185 | Drug product | 2026-07-27 | caaa826d4ba7… |
OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.
| Brand | Generic | Manufacturer | SPL set ID | Effective date | Available safety fields | Join |
|---|---|---|---|---|---|---|
| POTASSIUM PHOSPHATES | POTASSIUM PHOSPHATES IN SODIUM CHLORIDE | Amneal Pharmaceuticals LLC | dce22c93-aa48-48a9-ac8b-716400d33c9e | 2025-09-01 | Warnings, Adverse reactions | 70121-1722-9 70121-1722 70121172209 def7f258-3637-4362-b77d-e16904796cd5 dce22c93-aa48-48a9-ac8b-716400d33c9e |
Adverse event summaries are temporarily unavailable. Other product information remains available.